Get the Stockscreener App
0.95
10.72%
0.092
After Hours:
.97
0.02
+2.11%
Durect Corp stock is traded at $0.95, with a volume of 203.87K.
It is up +10.72% in the last 24 hours and up +5.14% over the past month.
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
See More
Previous Close:
$0.858
Open:
$0.85
24h Volume:
203.87K
Relative Volume:
2.29
Market Cap:
$29.49M
Revenue:
$8.59M
Net Income/Loss:
$-17.07M
P/E Ratio:
-0.6169
EPS:
-1.54
Net Cash Flow:
$-21.90M
1W Performance:
+26.67%
1M Performance:
+5.14%
6M Performance:
-36.24%
1Y Performance:
+89.24%
1-Day Range:
$0.81
$1.022
1-Week Range:
$0.7362
$1.022
52-Week Range:
$0.4938
$1.88
Durect Corp Stock (DRRX) Company Profile
Name
Durect Corp
Sector
Phone
(408) 777-1417
Address
10240 BUBB ROAD, CUPERTINO, CA
Compare DRRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
0.95 | 29.49M | 8.59M | -17.07M | -21.90M | -0.61 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-12-20 | Initiated | ROTH Capital | Buy |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jan-31-20 | Initiated | B. Riley FBR | Buy |
| Nov-18-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-18 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-20-17 | Reiterated | Laidlaw | Buy |
| Oct-20-17 | Downgrade | Stifel | Buy → Hold |
| Jul-12-17 | Upgrade | Stifel | Hold → Buy |
| Feb-28-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-16 | Initiated | Rodman & Renshaw | Buy |
| May-01-15 | Reiterated | Cantor Fitzgerald | Buy |
| May-01-15 | Reiterated | Stifel | Buy |
| Mar-25-13 | Initiated | Stifel | Buy |
| Nov-01-12 | Downgrade | C.K. Cooper | Buy → Hold |
| Aug-17-12 | Initiated | C.K. Cooper | Buy |
| Jun-23-09 | Initiated | Caris & Company | Buy |
| Mar-26-09 | Initiated | Wedbush Morgan | Hold |
View All
Durect Corp Stock (DRRX) Latest News
Durect (DRRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
DURECT Corp expected to post a loss of 17 cents a shareEarnings Preview - XM
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
DURECT Corp sells ALZET product line to Lafayette - TradingPedia
Durect announces sale of Alzet line of osmotic pumps to LIC for $17.5M - TipRanks
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million - PR Newswire
DURECT Corporation (NASDAQ:DRRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corporation reports Q3 2024 financials - Investing.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... - Yahoo Finance
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... By GuruFocus - Investing.com Canada
Durect: Q3 Earnings Snapshot - Houston Chronicle
Durect Corp Q3 2024 Earnings: GAAP EPS of -$0.14 Misses Estimates, Revenue at $1.9 Million Below Expectations - GuruFocus.com
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Durect reports Q3 EPS (14c), consensus (17c) - TipRanks
DURECT Q3: $4.3M Loss, Plans Phase 3 Trial Amid Funding Needs & License Agreement End | DRRX Stock News - StockTitan
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - StockTitan
DRRXDurect Corp Latest Stock News & Market Updates - StockTitan
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 - StockTitan
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ... - Yahoo Finance
Durect Corp Annual Meeting Decisions and Shareholder Votes - TipRanks
H.C. Wainwright maintains Neutral rating on Durect shares post FDA meeting - Investing.com
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - PR Newswire
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - PR Newswire
Durect Corp (NQ: DRRX - Financial Content
Durect (FRA:DC8A) Total Inventories : €2.30 Mil (As of Jun. 2024) - GuruFocus.com
DURECT Co. (NASDAQ:DRRX) Expected to Post Q3 2024 Earnings of ($0.14) Per Share - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corp reports steady Q2 financials, plans Phase III trial - Investing.com India
Durect: Q2 Earnings Snapshot - Houston Chronicle
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - PR Newswire
DURECT (DRRX) Set to Announce Quarterly Earnings on Tuesday - Defense World
DURECT Co. (NASDAQ:DRRX) Receives $27.50 Average Target Price from Brokerages - American Banking and Market News
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update - StockTitan
ProAssurance Co. (NYSE:PRA) Shares Bought by CANADA LIFE ASSURANCE Co - Defense World
DURECT (DRRX) Stock Price, News & Analysis - MarketBeat
Altair Engineering (NASDAQ:ALTR) Stock Rating Lowered by The Goldman Sachs Group - Defense World
DURECT (NASDAQ:DRRX) Stock Price Passes Above Two Hundred Day Moving Average of $1.13 - MarketBeat
DURECT Co. (NASDAQ:DRRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DURECT (NASDAQ:DRRX) Stock Price Passes Above 200-Day Moving Average of $1.01 - Defense World
Durect - The Pharma Letter
DURECT Corporation Announces Presentations in Upcoming Investor Conferences - Quantisnow
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update - Quantisnow
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update - Quantisnow
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol ... - Quantisnow
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update - Quantisnow
Durect Corp Stock (DRRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):